ACAD vs BAC Stock Comparison
ACAD currently leads BAC in this stock comparison, with AIQ scores of 65 vs 46. The clearest difference is quality.
What is the main difference between ACAD and BAC?
ACAD leads the current stock comparison as ACADIA Pharmaceuticals Inc., with the clearest separation coming from quality and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
ACADIA Pharmaceuticals Inc. vs Bank of America Corporation
ACAD leads
ACAD leads by 19 AIQ points, primarily on Quality and Momentum.
Competitive: 3 of 6 evidence groups support ACAD, and its signal state is cleanly positive.
ACADIA Pharmaceuticals Inc.
Bank of America Corporation
The Algovestiq AIQ Score currently favors ACAD over BAC, 65 versus 46 as of Oct 21, 2026. ACAD's advantage is driven primarily by stronger quality and momentum. ACAD also shows the weaker technical structure relative to its 50-day moving average. 3 of 6 covered evidence groups favor ACAD today, and the comparison is rated Competitive on stability: only 3 of 6 covered evidence groups agree. ACAD lead: Stable — the AIQ differential has held near 19 points over 30 sessions.
Compare ACADIA Pharmaceuticals Inc. and Bank of America Corporation across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Total return with distributions reinvested, from daily closes.
Total return comparison
Growth of $10,000, distributions reinvested
Split-adjusted closes; each distribution is reinvested at the close on its ex-dividend date. Taxes and trading costs are not modeled.
Compare ACAD and BAC against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Quality92 vs 49ACAD +43
- Momentum45 vs 24ACAD +21
- Risk Resilience60 vs 58Even
- Value57 vs 57Even
3 of 6 evidence groups favor ACAD. ACAD’s edge is concentrated in quality and momentum.
What changed since the last close
Latest scored session 2026-10-20, compared against the prior scored session 2026-10-19.
Largest factor move: Momentum +6
No signal started or stopped since the prior session; its 4 active signals are unchanged.
Largest factor move: Risk Resilience +1, not enough on its own to move the overall score.
No signal started or stopped since the prior session; its 5 active signals are unchanged.
ACAD's lead widened by 2 AIQ points in the latest session.
Deeper signal detail for each name lives on its own signals page — ACAD and BAC both carry a full feed there.
The central trade-off
ACAD (ACADIA Pharmaceuticals Inc.): the stronger current systematic profile, led by quality and momentum.
BAC (Bank of America Corporation): the counter-case, on technicals.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
ACADACAD on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
ACADACAD on combined revenue and EPS growth.
Value
EvenThe two are level on Value.
Momentum
ACADACAD on the Momentum factor, by 21 points.
Lower downside
BACBAC carries the lower 1-month annualized volatility.
Analyst upside
ACADACAD on implied upside to the consensus price target.
AIQ vs Wall Street
Where the systematic read and the analyst consensus line up — and where they do not.
| Measure | ACAD | BAC | Note |
|---|---|---|---|
| Implied upside to target | +63.3% | +30.5% | ACAD has more room |
| Target dispersion | +104.6% | +22.6% | Lower is tighter analyst agreement |
| Consensus | Buy | Buy | Context, not a primary driver |
| Analysts covering | 11 | 11 | Higher coverage generally improves confidence |
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
3 of 6 covered evidence groups favor ACAD. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | ACAD | 65 vs 46 |
| Fundamentals | ACADon balance | revenue growth 14.9% vs -3.3%; EPS growth 8% vs -23.8%; TTM ROE 32.4% vs 10.7%; gross margin 91.1% vs 60.4%; operating margin 7.6% vs 22.4% — ACAD takes 4 of 5 decided legs, not all of them |
| Valuation | Even | Value 57 vs 57 |
| Technicals | BAC | Price vs 50-day -19.8% vs -13.2%; vs 200-day -14.6% vs -8.1% |
| Risk Resilience | Even | Risk Resilience 60 vs 58 |
| Analyst expectations | ACAD | Target upside 63.3% vs 30.5% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of ACAD and BAC and are excluded from the count.
AIQ Decision Stability
The two are close enough that your objective, not the score, should decide.
- The AIQ gap is wide at 19 points. (supports the conclusion holding)
- Only 3 of 6 covered evidence groups agree. (argues the conclusion is provisional)
- The lead has been steady session to session. (supports the conclusion holding)
- The leader's signal state is cleanly positive. (supports the conclusion holding)
- Analyst targets on the leader are widely dispersed. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on ACAD.
How the comparison changed
120 daily snapshots · Jun 21 – Oct 20ACAD lead: Stable — the AIQ differential has held near 19 points over 30 sessions.
- Today
- ACAD +19
- 65 vs 46
- 7 sessions ago
- ACAD +21
- 62 vs 41
- 30 sessions ago
- ACAD +19
- 59 vs 40
- 90 sessions ago
- ACAD +19
- 73 vs 54
The lead has not changed hands in this window.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
2 bullish / 0 bearish / 2 neutral
Only ACAD
- ATR Expansion - Breakout Mode — neutral, volatility, short horizon (3.89%)
- MACD Bullish Crossover — bullish, momentum, short horizon
2 bullish / 2 bearish / 1 neutral, conflicted
Only BAC
- Keltner Channel Breakdown — bearish, volatility, short horizon
- RSI Oversold - Potential Bounce — bullish, momentum, short horizon
- MACD Bearish Crossover — bearish, momentum, short horizon
Both carry 2 more signals that do not separate them: Bollinger Band Squeeze, Golden Cross Active.
BAC is conflicted, so the timing case there is weaker than the score alone suggests.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Price is down while the AIQ Score moved up 2 points over the same session — price and model disagree (price -1.22%, AIQ +2 points).
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +0.28%, AIQ 0 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1BAC closes the Quality gap — currently 43 points behind, the largest single contributor to ACAD's edge.
- 2BAC's Keltner Channel Breakdown resolves — a bearish volatility rule currently active against it.
- 3ACAD's Golden Cross Active breaks down — it is the strongest rule currently supporting the verdict.
- 4A regime shift changes factor weighting — Quality and Value carry the heaviest weights in the composite, so a rotation toward either would move the result most.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
ACAD leads on balance| Metric | ACAD | BAC |
|---|---|---|
| Revenue growth (YoY) | 14.9% | -3.3% |
| EPS growth (YoY) | 8% | -23.8% |
| Gross margin | 91.1% | 60.4% |
| Operating margin | 7.6% | 22.4% |
| Return on equity (TTM) | 32.4% | 10.7% |
| Debt to equity | 0.06 | 1.28 |
Performance
BAC leads 5 of 6 windows| Metric | ACAD | BAC |
|---|---|---|
| 1 week (5 sessions) | 9.8% | -6.2% |
| 1 month (20 sessions) | -22.6% | -9.9% |
| 3 months (63 sessions) | -18.1% | -16.5% |
| 6 months (126 sessions) | -6.2% | -5.3% |
| Year to date | -23.5% | -7.9% |
| 1 year (252 sessions) | -0.9% | 0.4% |
Technicals
BAC has the stronger structure| Metric | ACAD | BAC |
|---|---|---|
| RSI (14) | 52.7 | 25.5 |
| ADX (14) | 51 | 48.6 |
| Price vs 50-day | -19.8% | -13.2% |
| Price vs 200-day | -14.6% | -8.1% |
| Volatility (1M, annualized) | 55.4% | 21.8% |
Risk
Split| Metric | ACAD | BAC |
|---|---|---|
| Beta | 0.71 | 0.75 |
| Sharpe ratio | 0.04 | -0.13 |
| Sortino ratio | 0.05 | -0.16 |
| Max drawdown | -39.1% | -22.3% |
| Current drawdown | -33.1% | -21.9% |
| Annualized volatility | 38.7% | 21.9% |
| Value at risk (95%) | -3.5% | -2.5% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, ACAD or BAC?
On the Algovestiq AIQ Score, ACAD is the stronger of the two as of Oct 21, 2026, scoring 65 against BAC's 46. The edge comes from quality and momentum. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is ACAD or BAC the better buy right now?
ACAD carries the stronger systematic profile as of Oct 21, 2026, and the comparison is rated Competitive — 3 of 6 covered evidence groups agree. A Competitive rating means the two are close enough that your objective, not the score, should decide.
Why does the AIQ Score favor ACAD over BAC?
The composite weights Quality, Value, Momentum and Risk Resilience. ACAD leads Quality by 43 points; ACAD leads Momentum by 21 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, ACAD or BAC?
Analyst price targets imply +63.3% upside for ACAD and +30.5% for BAC, so the Street currently favors ACAD. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, ACAD or BAC?
Neither name separates on the peer-relative Value factor. The two are level on Value. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, ACAD or BAC?
ACAD on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, ACAD or BAC?
ACAD on the Momentum factor, by 21 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, ACAD or BAC?
BAC is the more resilient of the two, so the other name carries the higher downside risk. BAC carries the lower 1-month annualized volatility. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is ACAD more profitable than BAC?
The profitability evidence is mixed: gross margin 91.1% vs 60.4%; operating margin 7.6% vs 22.4%; ttm roe 32.4% vs 10.7%. ACAD leads on two measures and BAC on one measure, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.
Is ACAD's lead over BAC getting stronger or weaker?
ACAD lead: Stable — the AIQ differential has held near 19 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-06-21 and 2026-10-20. The lead has not changed hands in that window.
What would change the ACAD vs BAC verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: BAC closes the Quality gap — currently 43 points behind, the largest single contributor to ACAD's edge; BAC's Keltner Channel Breakdown resolves — a bearish volatility rule currently active against it; ACAD's Golden Cross Active breaks down — it is the strongest rule currently supporting the verdict; a regime shift changes factor weighting — Quality and Value carry the heaviest weights in the composite, so a rotation toward either would move the result most.
What do the current signals say about ACAD and BAC?
ACAD: 2 bullish / 0 bearish / 2 neutral. BAC: 2 bullish / 2 bearish / 1 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on ACAD is Golden Cross Active (bullish, long horizon). On BAC it is Golden Cross Active (bullish, long horizon).
Compare ACAD and BAC with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.